度拉糖肽对老年 2 型糖尿病患者血糖控制和膝骨关节炎疼痛的双重影响。
Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.
机构信息
Department of Diabetes & Allergy-Asthma, Therapeutics Specialty Clinic, Kolkata, West Bengal, India.
Department of Diabetes & Endocrinology, Apollo Sugar Clinic Kolkata, West Bengal, India.
出版信息
Pain Manag. 2024;14(7):365-373. doi: 10.1080/17581869.2024.2402214. Epub 2024 Sep 20.
Abstract
This study aims to evaluate the dual benefits of dulaglutide in improving glycemic control and reducing knee OA pain. Elderly T2DM patients diagnosed with bilateral knee OA on conventional OA treatment for at least 3 months were studied for their glycemic metrics, OA pain scores and NSAID consumption at baseline, 3 months and 6 months. Significant improvements in glycemic control were observed, HbA1c decreased from 8.7% to 6.5% over 6 months. Pain scores, NSAID, body weight and BMI showed substantial reductions over time. Positive correlation (r = 0.73, < 0.001) was found between glycemic control and pain reduction. Dulaglutide improves glycemic control, knee joint OA pain and weight management in elderly patients with T2DM.
摘要
本研究旨在评估度拉糖肽在改善血糖控制和减轻膝骨关节炎疼痛方面的双重益处。对接受常规骨关节炎治疗至少 3 个月的双侧膝骨关节炎的老年 2 型糖尿病患者进行研究，以评估其血糖指标、骨关节炎疼痛评分和 NSAID 消耗情况，分别在基线、3 个月和 6 个月时进行评估。结果显示，患者的血糖控制得到显著改善，HbA1c 在 6 个月内从 8.7%降至 6.5%。疼痛评分、NSAID、体重和 BMI 随时间呈显著下降趋势。血糖控制与疼痛减轻之间存在正相关关系（r = 0.73，<0.001）。度拉糖肽可改善老年 2 型糖尿病患者的血糖控制、膝关节骨关节炎疼痛和体重管理。
相似文献
1
Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.度拉糖肽对老年 2 型糖尿病患者血糖控制和膝骨关节炎疼痛的双重影响。
Pain Manag. 2024;14(7):365-373. doi: 10.1080/17581869.2024.2402214. Epub 2024 Sep 20.
2
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的疗效与安全性：一项系统评价和混合治疗比较分析
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
3
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review.髋、膝或髋膝骨关节炎患者的运动干预和患者信念：一项混合方法综述
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD010842. doi: 10.1002/14651858.CD010842.pub2.
4
WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee.撤回：用于治疗膝关节骨关节炎的非阿司匹林非甾体抗炎药。
Cochrane Database Syst Rev. 2007 Jul 18;2006(1):CD000142. doi: 10.1002/14651858.CD000142.pub2.
5
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶（DPP）-4抑制剂和胰高血糖素样肽（GLP）-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
6
Celecoxib for osteoarthritis.塞来昔布用于骨关节炎
Cochrane Database Syst Rev. 2017 May 22;5(5):CD009865. doi: 10.1002/14651858.CD009865.pub2.
7
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
8
How Does Shame Relate to Clinical and Psychosocial Outcomes in Knee Osteoarthritis?羞耻感与膝关节骨关节炎的临床及心理社会结局有何关联？
Clin Orthop Relat Res. 2025 Apr 1;483(4):558-570. doi: 10.1097/CORR.0000000000003329. Epub 2024 Dec 3.
9
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.新型 2 型糖尿病血糖控制药物：系统评价和经济评估。
Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360.
10
Antidepressants for hip and knee osteoarthritis.抗抑郁药治疗髋膝关节骨关节炎。
Cochrane Database Syst Rev. 2022 Oct 21;10(10):CD012157. doi: 10.1002/14651858.CD012157.pub2.
引用本文的文献
1
Exploring new therapeutic drugs for osteoarthritis and osteoporosis: Glucagon-like peptide-1 receptor agonists: A review.探索骨关节炎和骨质疏松症的新型治疗药物：胰高血糖素样肽-1受体激动剂：综述
Medicine (Baltimore). 2025 Jul 18;104(29):e43239. doi: 10.1097/MD.0000000000043239.
2
Advances in GLP-1 receptor agonists for pain treatment and their future potential.用于疼痛治疗的胰高血糖素样肽-1受体激动剂的进展及其未来潜力。
J Headache Pain. 2025 Feb 27;26(1):46. doi: 10.1186/s10194-025-01979-4.
3
Harnessing the Power of Water: A Scoping Review of Hydrokinesiotherapy as a Game-Changer in Knee Osteoarthritis Management.利用水的力量：水运动疗法在膝关节骨关节炎管理中作为变革性方法的范围综述
J Clin Med. 2024 Sep 28;13(19):5811. doi: 10.3390/jcm13195811.
本文引用的文献
1
Trim14-IκBα Signaling Regulates Chronic Inflammatory Pain in Rats and Osteoarthritis Patients.Trim14-IκBα 信号通路调控大鼠慢性炎性痛及骨关节炎患者的疼痛
Neuroscience. 2024 Jun 7;548:39-49. doi: 10.1016/j.neuroscience.2024.04.015. Epub 2024 May 1.
2
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.胰高血糖素样肽-1：一种多效抗炎剂。
Front Immunol. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209. eCollection 2023.
3
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.胰高血糖素样肽-1 受体激动剂作为一种通过减轻体重介导的膝骨关节炎的疾病修正治疗：来自上海骨关节炎队列研究的结果。
Ann Rheum Dis. 2023 Sep;82(9):1218-1226. doi: 10.1136/ard-2023-223845. Epub 2023 May 31.
4
Osteoarthritis: pathogenic signaling pathways and therapeutic targets.骨关节炎：发病信号通路和治疗靶点。
Signal Transduct Target Ther. 2023 Feb 3;8(1):56. doi: 10.1038/s41392-023-01330-w.
5
Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis.比较度拉糖肽与一线降糖药物在亚洲 2 型糖尿病患者中的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2022 Oct 31;12(1):18281. doi: 10.1038/s41598-022-22263-4.
6
Interactions Between Diabetes Mellitus and Osteoarthritis: From Animal Studies to Clinical Data.糖尿病与骨关节炎之间的相互作用：从动物研究到临床数据
JBMR Plus. 2022 Apr 23;6(5):e10626. doi: 10.1002/jbm4.10626. eCollection 2022 May.
7
The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome.GLP-1 受体激动剂在多囊卵巢综合征伴肥胖胰岛素抵抗中的作用。
Int J Mol Sci. 2022 Apr 14;23(8):4334. doi: 10.3390/ijms23084334.
8
Prevalence, Awareness, Treatment and Control of Diabetes in India From the Countrywide National NCD Monitoring Survey.来自全国非传染性疾病监测调查的印度糖尿病患病率、知晓率、治疗率及控制率
Front Public Health. 2022 Mar 14;10:748157. doi: 10.3389/fpubh.2022.748157. eCollection 2022.
9
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?靶向GLP-1/GLP-1R轴治疗骨关节炎：新机遇？
J Orthop Translat. 2022 Feb 25;32:121-129. doi: 10.1016/j.jot.2022.02.001. eCollection 2022 Jan.
10
Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis.利拉鲁肽，一种胰高血糖素样肽1受体激动剂，在骨关节炎中发挥镇痛、抗炎和抗降解作用。
Sci Rep. 2022 Jan 28;12(1):1567. doi: 10.1038/s41598-022-05323-7.
Zotero 插件